Inhibrx Biosciences, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €172.24K -88.9% €1.45B -799.2% 843,786.0% +8.6K pp -€165.18M +1.6% -95,906.0% -850 pp
    €1.55M -17.4% -€207.85M +66.2% -13,408.9% -67 pp -€162.52M +64.7% -10,484.2% -52 pp
    €1.88M -69.4% -€125.07M +77.6% -6,667.9% -55 pp -€98.70M +44.2% -5,262.4% -41 pp
    €6.14M -44.4% -€70.42M +8.1% -1,147.6% -5.6 pp -€68.43M +70.5% -1,115.2% -7.5 pp
    €11.03M +40.9% -€65.14M +47.2% -590.5% -0.25 pp -€40.13M +54.0% -363.9% -0.31 pp
    €7.83M +21.2% -€44.26M +64.9% -565.3% -1.5 pp -€26.07M +39.7% -332.9% -0.44 pp
    €6.46M -5.7% -€26.84M +60.3% -415.5% -1.7 pp -€18.66M +24.4% -288.8% -0.70 pp
    €6.85M +19.2% -€16.74M +135.1% -244.6% -1.2 pp -€14.99M -2.7% -219.0% +0.49 pp
    €5.74M -€7.12M -124.0% -€15.41M -268.4%

    Notifications